Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

November 16, 2015

The Phase 1 study is a dose escalation trial, which will enroll up to 50 patients with certain cancers, including metastatic disease. Patients with solid tumors will receive PLX3397 orally in cycles of 28 days. The primary objective of this trial is to assess the safety, tolerability and pharmacokinetic profile of PLX3397. An additional follow-on Phase 1b study is planned in patients with rheumatoid arthritis. Pending completion of the Phase 1 studies, Plexxikon plans to explore further clinical development potentially both in cancer and rheumatoid arthritis patients. More information about the trial for metastatic disease is available at www.clinicaltrials.

???PLX3397 is the sixth IND candidate to be generated by Plexxikon, further validating our platform as a discovery engine. It represents the first molecule among a portfolio of compounds with distinct and rational profiles selective for these targets,??? stated K. Peter Hirth, Ph.D., chief executive officer of Plexxikon. ???Given the high degree of selectivity of our kinase inhibitors and potential improved safety profile, we may now address a wide range of diseases with significant unmet needs, including cancer and rheumatoid arthritis. In addition, the brain penetrability of PLX3397 potentially makes this an attractive drug for brain cancer and neuro-inflammatory diseases, such as Alzheimer??�s Disease and multiple sclerosis.???

Source: Plexxikon